PTGX - Protagonist Therapeutics Inc
This page shows which of the focused investors we track hold PTGX and how their positions changed, so you can see how much conviction the group has in the stock.
In Q1 2026 it was held by 2 managers with an aggregate reported value of $19.4M, which is 0.00% of the combined portfolio.
As of Q1 2026, 2 tracked institutional managers held PTGX (Protagonist Therapeutics Inc) with an aggregate reported value of $19.4M — 0.00% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades PTGX — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q1 2026
- Ticker
- PTGX
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Stanley Druckenmiller - Duquesne Family Office LLC | 0.57% | - | 159,700 | $16.83M |
| 2 | Polen Capital Management - Polen Capital Management | 0.02% | Add +19.6% | 24,337 | $2.57M |
Loading holder history for PTGX…